Displaying items by tag: harbert institute for innovation and entrepreneurship

UAB received the IEP Innovation award, recognizing exemplary initiatives spurring innovation, entrepreneurship and technology-based economic development.
This new grant will be used to develop a full-scale family of devices for inhaled nitric oxide delivery for patients with pulmonary hypertension that can be used in health care facilities and for at-home care.
The Alabama Innovation Corporation awarded two UAB startups with grants during the second round of Innovate Alabama Supplemental Grant awards.
The panel discussion will help navigate through the daunting, complicated process of launching a startup for passionate entrepreneurs.
The grant validates the science of Alveolus Bio, and the funds will support development of first-of-its-kind inhaled biotherapeutics to treat chronic lung diseases.
The funded project began Jan. 1 and is expected to run for two years. The proposal focuses on developing a novel dental pulp capping material by improving bioactivity of pulp tissue while achieving ideal mechanical properties.
The spinoff company, IN8bio Inc., uses proprietary drug-resistant immunotherapy licensed in part from UAB. Glioblastoma is the most aggressive type of cancer originating in the brain.
The Zorro-Flow Inc. is the newest startup from the UAB Harbert Institute for Innovation and Entrepreneurship. The device is the first external catheter to collect urine effectively, safely and comfortably from critically ill female neonates and children.
Thaddaeus Kwan, Ph.D., became one the first Innovate fellows in the Harbert Institute for Innovation and Entrepreneurship while a postdoc at UAB. He now works in HIIE as a project analyst — and heads the Fellows program.
All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial have exceeded both their median and expected progression-free survivals. Two patients, to date, have exceeded their expected overall survival.
Researchers have been awarded a $2.6 million, four-year National Institutes of Health grant to evaluate a safer and more durable stent design, using techniques licensed through the UAB Harbert Institute for Innovation and Entrepreneurship by the UAB spinoff company Endomimetics LLC.
The monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness, potentially lasting a year or more when used in humans.
Page 1 of 2